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Background: Hydroxychloroquine and chloroquine may reduce the risk of cancer as they 
inhibit autophagy, in particular, in people with connective tissue diseases.
Methods: The hazard ratios of cancers, metastases, and death were assessed in adults with 
connective tissue diseases prescribed hydroxychloroquine/chloroquine for at least 1 year in 
comparison with unexposed individuals with the same underlying conditions. A competing risk 
survival regression analysis was performed. Data were extracted from the Health Improvement 
Network UK primary care database.
Results: Eight thousand nine hundred and ninety-nine individuals exposed to hydroxychloroquine 
(98.6%) or chloroquine (1.4%) and 24,118 unexposed individuals were included in the study 
(median age: 56 [45–66] years, women: 76.8%). When compared to the unexposed group, 
individuals exposed to hydroxychloroquine/chloroquine were not at lower risk of non-skin 
cancers (adjusted sub-distribution hazard ratio [sHR]: 1.04 [0.92–1.18], p=0.54), hematological 
malignancies (adjusted sHR: 1.00 [0.73–1.38], p=0.99), or skin cancers (adjusted sHR: 0.92 
[0.78–1.07], p=0.26). The risk of metastasis was not significantly different between the two 
groups. However, it was significantly lower during the exposure period when compared with 
the unexposed (adjusted sHR: 0.64 [0.44–0.95] for the overall population and 0.61 [0.38–1.00] 
for those diagnosed with incident cancers). The risk of death was also significantly lower in 
those exposed to hydroxychloroquine/chloroquine (adjusted HR: 0.90 [0.81–1.00] in the overall 
population and 0.78 [0.64–0.96] in those diagnosed with incident cancer).
Conclusion: Individuals on long-term exposure to hydroxychloroquine/chloroquine are not at 
lower risk of cancer. However, hydroxychloroquine/chloroquine may lower the risk of metastatic 
cancer and death.
Keywords: antimalarial drugs, cancer, death, connective tissue diseases
Background
For decades, chloroquine and hydroxychloroquine have been used to treat malaria. 
Nowadays, they are mainly used to treat connective tissue diseases. More recently, 
their potential use as anticancer agents has led to renewed interest in these old drugs. 
Hydroxychloroquine and chloroquine are thought to have antitumor properties mainly 
because they inhibit autophagy, although they can also affect the growth and spread of 
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tumor cells independent of this mechanism.1–4 Autophagy is a 
complex cellular mechanism that is thought to play a dual role 
in tumor growth progress – that is, preventing tumor initiation 
by suppressing chronic tissue damage, inflammation, and 
genome instability and sustaining tumor metabolism, growth, 
and survival via nutrient recycling.4–6 However, most of the 
physiological functions of autophagy are still unclear, even 
though tremendous advances have been made during the past 
decade. Thus, in October 2016, the Nobel Prize in Physiol-
ogy or Medicine was awarded to Yoshinori Ohsumi “for his 
discoveries of mechanisms for autophagy”. Using autophagy 
as a tumor treatment target is under investigation, and there 
are many ongoing trials assessing the clinical benefits of 
adding hydroxychloroquine or chloroquine to conventional 
therapies in individuals with solid or hematologic cancers 
(unpublished data, 2017). The limited data on this topic are 
encouraging,7–15 in particular, in people with connective tis-
sue diseases.9 Most of these studies, however, are Phase I or 
Phase II studies and are limited by small numbers of patients.
The aim of this cohort study was to assess the effects of 
hydroxychloroquine or chloroquine as prescribed in people 
with connective tissue diseases on 1) incident risk of cancers, 
2) incident risk of metastases, and 3) all-causes mortality.
Methods
Study design
The Health Improvement Network (THIN) is a primary care 
database of anonymized general practice records from the 
early 1990s to the present day on more than 12 million indi-
viduals from nearly 700 practices in the UK. Participating 
general practitioners systematically and prospectively enter 
clinical information on individuals, including demographic 
data, diagnoses, and prescriptions so that the database 
provides a longitudinal medical record for each individual. 
THIN is a representative of the UK population and the 
clinical diagnostic and prescribing data compare favorably 
with external statistics and other independent studies.16,17 
Since these data are entered in routine general practice, they 
reflect “real-life” clinical care. We used data from January 1, 
1990, to December 31, 2015 from all general practices that 
contributed to the database during this period. We further 
restricted our data to the time when there was evidence that 
the practices were entering most clinical information on 
their computer systems.18 All diagnoses and symptoms were 
recorded in THIN using the Read classification system.19 This 
Read classification was used to create medical code lists that 
enabled us to identify cases of non-skin cancers, hematologi-
cal malignancies, skin cancers, or metastasis.20
Exposed and unexposed populations
All individuals in our study were ≥18 years. Individuals were 
included in the exposed sample if they had connective tissue 
diseases and had been prescribed hydroxychloroquine or 
chloroquine for at least 1 year at a significant daily dosage 
(i.e., mean daily dosage over the exposure period ≥100 mg 
for chloroquine and ≥200 mg for hydroxychloroquine). 
The medical diagnosis recorded on the date of starting 
hydroxychloroquine or chloroquine was used as the indication 
for the drug prescription. If there were no medical diagnoses 
recorded on this date, we searched for a diagnosis of 
connective tissue disease (or light eruption/photosensitivity) 
as entered on the records for up to 1 year prior or after this 
prescription. We selected only those who started the drug at 
least 6 months after their registration with the general practice 
in order to capture people with incident rather than prevalent 
treatment. The start of at-risk period (i.e., hereafter called 
“start date”) was defined as the first day of the first prescription 
of hydroxychloroquine or chloroquine. Individuals were 
eligible to be included in the control, unexposed sample if they 
had never been exposed to chloroquine, hydroxychloroquine, 
quinine, quinacrine, or mefloquine, but were suffering from 
the same underlying condition as the exposed individuals. We 
selected up to three unexposed individuals for every exposed 
individual stratified within 5-year age bands, gender, and 
the underlying condition. For each unexposed individual, a 
uniformly randomly selected “start date” (i.e., start of the 
at-risk period) was defined as at least 6 months after their 
registration. Individuals had to have at least 1 year follow-up 
after “start date” to be included in the unexposed sample.
Study outcomes
We examined five prespecified outcomes: incident cases of 
1) non-skin, non-hematological cancers (excluding in situ 
neoplasia), 2) hematological malignancies, 3) skin cancers 
(excluding in situ neoplasia), 4) metastases, and 5) all-cause 
mortality. The first record of each outcome was taken into 
account for the analyses. Cancers or metastases were defined 
as incident when there was no previous record of cancer or 
metastasis in the medical file within the previous 5 years. 
Lastly, we searched for any records of death and date of 
death for all individuals included in our study population.21
Covariates of interest
For each individual, we extracted data on social deprivation 
(i.e., Townsend deprivation index); body mass index (based 
on the nearest record of “start date”); smoking status (based 
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Antimalarial drugs and cancer
of diabetes, hypertension, or any cancer before “start 
date”. Further, we assessed the number of prescriptions of 
methotrexate, azathioprine, glucocorticoids, nonsteroidal 
antiinflammatory drugs (NSAIDs), vitamin D, and metformin 
before the record of malignancy, metastases, or death (for 
those with an outcome) or randomly selected dates during 
at-risk period (for those without these outcomes).
Statistical analyses
Baseline variables are reported as medians (interquartile 
range [IQR]) for continuous variables or counts (percentages) 
for categorical variables. Two-sided p-value ≤0.05 was 
considered significant.
Data on associations between hydroxychloroquine/
chloroquine exposure and the risk of incident cancers or 
metastases were analyzed using competing risk regression 
using the Fine and Gray method (with death as a competing 
event). The sub-distribution hazard ratios (sHRs) for 
competing risks of malignancies/metastases and all-cause 
mortality were obtained. Regarding the risk of metastases, 
the analyses were f irst run in the overall population. 
Then they were conducted in a subgroup of individuals 
diagnosed with cancer (excluding basal cell carcinoma and 
hematological malignancies) within 3 years before “start 
date” as we hypothesized that cancers occurring during 
exposure to the drugs may be more “resistant” to the drug 
than those occurring outside exposure. Lastly, the analyses 
were run in the subgroup of individuals diagnosed with 
incident cancer after “start date”. For these individuals, the 
start of at-risk period for metastasis was the date of cancer. 
The last step of our study was to compare the risk of death 
in the exposed and unexposed groups. This was performed 
using multivariable Cox proportional hazard models, both 
in the overall population and in the subgroup of individuals 
diagnosed with incident cancer after “start date”. As for 
metastasis, the start of at-risk period for this subgroup 
analysis was the date of cancer diagnosis.
All the analyses were done by taking into account 
exposure both as a binary variable (exposed/unexposed) and 
as a time-varying variable. We did the latter as some exposed 
individuals may have been exposed for years before stopping 
the treatment.
We included age and sex as covariates in all the models, 
but for the other variables, we chose those associated with 
the outcome with a p-value ≤0.2 in univariate analyses 
(all covariates described in the previous paragraph were 
assessed). The proportional hazards assumption for Cox 
models was checked graphically using the Schoenfeld 
residuals. Linearity for continuous variables was checked 
by comparing two models, one with the linear term and the 
other with the categories using the log likelihood ratio test 
(when necessary, continuous variables were categorized). We 
examined whether the effect of exposure differed by age and 
gender by evaluating if there was a significant interaction 
between age or gender and exposure in the models. We 
looked for trend in the occurrence of malignancies according 
to the duration of exposure using the test for trend across 
ordered groups (Stata nptrend command).
All analyses were done using Stata, version 14.0. THIN 
scheme for obtaining patient data and providing them in ano-
nymized form to researchers was approved by the National 
Health Service South-East Multicentre Research Ethics 
Committee in 2002. The present study was approved by the 
THIN scientific review committee.
Sensitivity analyses
Since it can be hypothesized that comparing new 
hydroxychloroquine/chloroquine users to individuals never 
exposed to the drugs can create substantial bias, in particular 
selection bias, we also compared individuals chronically 
exposed to those who received hydroxychloroquine for 
<1 year and stopped it, for instance, for inefficiency or 
occurrence of adverse events. To be eligible to be included 
in this shortly exposed group, individuals had to have at least 
1 year of follow-up after initiation of hydroxychloroquine, 
reflecting at least 1-year exposure of the chronically exposed 
individuals. Up to three shortly exposed individuals were 
selected for every chronically exposed individual stratified 




In total, 8,999 individuals exposed to hydroxychloroquine 
or chloroquine and 24,118 unexposed individuals were 
included in the study. The median age was 56 (45–66) 
years and 25,445 (76.8%) were women (Table 1). Most 
exposed individuals received hydroxychloroquine (n=8,871, 
98.6%). Only 128 individuals received chloroquine, with no 
hydroxychloroquine exposure during follow-up. The median 
duration of hydroxychloroquine/chloroquine exposure was 
37 (22–66) months (mean duration ± SD: 50±39 months).
Incident cases of primary malignancies
Respectively, 1,329 incident cases of non-skin cancers, 
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Table 1 Characteristics of the study population




Age (years) 56 (46–66) 55 (45–65)
Female, n (%) 6,909 (76.8) 18,536 (76.9)
“Start date” April 2010 (August 
2006–October 2012)
Dec 2009 (May 
2006–May 2012)
Duration of follow-up 
after “start date” (days)
1,509 (848–2,595) 1,475 (1,071–2,285)
Time between the end of 




 HCQ 307 (238–377) –
 CQ 169 (132–234) –
Underlying diseases, n (%) 
 Rheumatoid arthritis 6,139 (68.2) 15,995 (66.3)
  Systemic lupus 
erythematosus
1,644 (18.3) 4,932 (20.4)
 Sjogren syndrome 603 (6.7) 1,657 (6.9)
  Dermatomyositis/
polymyositis
29 (0.3) 26 (0.1)
  Other connective 
tissue diseasesa
531 (5.9) 1,358 (5.7)
 Light eruption 53 (0.6) 150 (0.6)
Number of prescriptions ofb
 Methotrexate 0 (0–71) 0 (0–50)
 Azathioprine 0 (0–2) 0 (0–0)
 Glucocorticoids 2 (0–60) 0 (0–34)
 NSAIDs 11 (0–108) 5 (0–85)
 Metformin 0 (0–13) 0 (0–10)
 Vitamin D 0 (0–43) 0 (0–25)
Smoking status, n (%) 
 Nonsmokers 4,133 (45.9) 11,800 (48.9)
 Ex-smokers 2,878 (32.0) 6,657 (27.6)
 Smokers 1,723 (19.2) 5,090 (21.1)
 Missing 265 (2.9) 571 (2.4)
Townsend deprivation index, n (%)
 0 (less deprived) 398 (4.4) 897 (3.7)
 1 2,304 (25.6) 6,540 (27.1)
 2 1,956 (21.8) 5,284 (21.9)
 3 1,809 (20.1) 4,675 (19.4)
 4 1,496 (16.6) 3,961 (16.4)
 5 (more deprived) 930 (10.3) 2,483 (10.3)
 Missing 106 (1.2) 278 (1.2)
BMI (kg/m2) 26.7 (23.4–31.0) 26.6 (23.4–30.8)
Past history of, n (%) 
 Non-skin cancer 431 (4.8) 1,063 (4.4)
  Hematological 
malignancy
64 (0.7) 112 (0.5)
 Skin cancer 277 (3.1) 751 (3.1)
 Hypertension 2,401 (26.7) 5,852 (24.3)
 Diabetes 840 (9.3) 1,943 (8.1)
Notes: aSystemic sclerosis, antiphospholipid syndrome, mixed and undifferentiated 
connective tissue diseases. bBefore the date of cancer with those with cancer 
and before a randomly selected date during follow-up for those without cancer. 
Continuous variables are reported as medians and interquartile range except for 
the number of medication prescriptions that are reported as medians and 5th–95th 
percentile range.
Abbreviations: BMI, body mass index; CQ, chloroquine; HCQ, hydroxychloroquine; 
NSAIDs, nonsteroidal antiinflammatory drugs, 
Table 2 Outcomes of interest




Incident outcomes after “start date”, n (%)
 Non-skin cancer 382 (4.2) 947 (3.9)
 Breast 89 (1.0) 219 (0.9) 
 Colon 44 (0.5) 99 (0.4)
 Prostate 39 (0.4) 79 (0.3)
 Lung 58 (0.6) 175 (0.7)
  Other or nonspecific 
codesa
152 (1.7) 375 (1.6)
 Hematological malignancy 59 (0.6) 139 (0.6)
 Skin cancer 270 (3.0) 689 (2.8)
 Metastasis 59 (0.6) 171 (0.7)
 Death 636 (7.1) 1,665 (6.9)
Median time between “start date” and record of incident 
outcome (days)
 Non-skin cancer 1,159 (573–2,258) 1,096 (623–1,786)
 Hematological malignancy 1,220 (670–2,229) 971 (469–1,766)
 Skin cancer 1,061 (489–2,099) 868 (436–1,585)
 Metastasis 1,399 (679–2,789) 1,205 (811–1,815)
 Death 1,611 (918–2,518) 1,461 (1,118–2,191)
Solid cancers diagnosed 
within 3 years before “start 
date”, n (%)
149 (1.6) 317 (1.3)
 Breast 42 (0.5) 96 (0.4)
 Colon 9 (0.1) 31 (0.1)
 Prostate 24 (0.3) 35 (0.1)
 Lung 12 (0.1)  15 (<0.1)
  Skin cancer (excluding 
basal cell carcinoma) 
23 (0.2) 53 (0.2)
  Other or nonspecific 
codesa
39 (0.4) 87 (0.4)
Median time between 
cancers diagnosed within 
3 years before “start date” 
and “start date” (days)
535 (314–816) 486 (224–781)
Note: aFor example,  “adenocarcinoma”.
incident cases of skin cancers were observed in the overall 
population (Table 2). There were no differences in incident 
non-skin cancers (adjusted sHR: 1.04 [0.92–1.18], p=0.54), 
hematological malignancies (adjusted sHR: 1.00 [0.73–1.38], 
p=0.99), or skin cancers (adjusted sHR: 0.92 [0.78–1.07], 
p=0.26) between exposed and unexposed individuals. Taking 
into account hydroxychloroquine/chloroquine exposure as a 
time-varying covariate (i.e., exposed period time compared 
to unexposed period time) gave similar results (Table 3). 
The annual incidence rates between the exposed and 
unexposed period times are reported in Table 4. An increasing 
temporal trend over time was observed for the unexposed 
group, while there was no clear increase over time during 
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Antimalarial drugs and cancer
Incident cases of metastases
In total, 230 incident cases of metastases were recorded in the 
overall population (Table 2). There was no difference in the risk 
of metastasis in the exposed and unexposed individuals except 
for those diagnosed with cancer within the 3 years before “start 
date” (adjusted sHR: 0.27 [0.10–0.80], p=0.02), even though 
the number of events was low (Table 5). However, the risk of 
metastasis was significantly lower during the exposed period 
when compared with the unexposed (adjusted sHRs: 0.64 
[0.44–0.95] for the overall population, 0.61 [0.38–1.00] for 
those diagnosed with incident cancers, and 0.26 [0.08–0.83] for 
those diagnosed with cancer within 3 years before “start date”, 
respectively) (Table 5). For those with a diagnosis of metastasis 
recorded after the end of hydroxychloroquine/chloroquine 
exposure (n=27), the median time between the end of exposure 
and the record of metastasis was 484 (52–1791) days.
Table 3 Risk of incident malignancies occurring after “start date” – comparison of the hydroxychloroquine/chloroquine exposed and 
unexposed periods
Exposed time Unexposed time Crude sHR* p-value Adjusted sHR* p-value
 Time at risk (year)
Incidence rate (per 100 PY)
Time at risk (year)















1.02 (0.87–1.20) 0.79 0.94 (0.80–1.12)b 0.50
Notes: *Exposed compared to unexposed. aAdjusted on age, sex, underlying condition, smoking status, past history of cancer, deprivation index, and number of NSAIDs, 
metformin, vitamin D, glucocorticoids, methotrexate, and azathioprine prescriptions. bAdjusted on age, sex, underlying condition, smoking status, past history of cancer, 
deprivation index, and number of NSAIDs, vitamin D, glucocorticoids, methotrexate, and azathioprine prescriptions. 
Abbreviations: NSAIDs, nonsteroidal antiinflammatory drugs; PY, person-years; sHR, sub-distribution hazard ratios.
Table 4 Annual incidence rate of incident malignancies after 






(95% CI) per 
100 person-years
First year
 Unexposed time 24,040 163 0.68 (0.58–0.79)
 Exposed time  8,959  74 0.83 (0.66–1.04)
Second year
 Unexposed time 23,605 245 1.04 (0.92–1.18)
 Exposed time  7,364  75 1.02 (0.81–1.28)
Third year
 Unexposed time 21,017 259 1.23 (1.09–1.39)
 Exposed time 5,229  52 0.99 (0.76–1.30)
Fourth year
 Unexposed time 15,568 194 1.25 (1.08–1.43)
 Exposed time 3,829  42 1.10 (0.81–1.48)
Fifth year and over
 Unexposed time 42,101 499 1.19 (1.09–1.29)
 Exposed time 10,654 116 1.09 (0.91–1.31)





Crude sHR p-value Adjusted sHR p-value
Overall population, n (%) 59 (0.6) 171 (0.7) 0.88 (0.65–1.18) 0.38 0.91 (0.67–1.22)a 0.53
In those with incident cancer diagnosed 
after “start date”, n (%)*
40 (9.0) 112 (10.2) 0.87 (0.61–1.24) 0.44 0.87 (0.61–1.26)b 0.47
In those with cancer diagnosed within 
3 years before “start date”, n (%)*
4 (2.7) 31 (9.8) 0.28 (0.10–0.79) 0.02 0.27 (0.10–0.80)c 0.02
Exposed time
Time (year)




Incidence rate (per 
100 person-years)





0.62 (0.43–0.91) 0.01 0.64 (0.44–0.95)a 0.02






0.63 (0.39–1.02) 0.06 0.61 (0.38–1.00)b 0.05
In those with cancer diagnosed within 





0.27 (0.08–0.86) 0.02 0.26 (0.08–0.83)c 0.02
Notes: *Excluding hematological malignancies and basal cell carcinomas. aAdjusted on age, sex, underlying condition, smoking status, past history of cancer, deprivation 
index, and number of glucocorticoids, metformin, and vitamin D prescriptions. bAdjusted on age, sex, underlying condition, smoking status, deprivation index, and number of 
NSAIDs and metformin prescriptions. cAdjusted on age and sex.
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In total, 2,301 (6.9%) out of the 33,117 individuals died 
(Table 2). The risk of death was significantly lower in those 
exposed to hydroxychloroquine/chloroquine when compared 
to the unexposed (adjusted HRs: 0.90 [0.81–1.00] in the 
overall population and 0.78 [0.64–0.96] in those with newly 
developed cancer). However, as there was a significant 
interaction between exposure and age, separate analyses 
were conducted in those under 70 years and those over 70 
years, and the decrease in risk was observed only in those 
≤70 years (Table 6).
Sensitivity analyses
The characteristics of the 5,265 individuals shortly exposed 
to hydroxychloroquine are reported in Table S1. Results 
regarding incident malignancy and metastases were very 
similar to those found when comparing the chronically 
exposed individuals to the unexposed (Table S2). The risk 
of metastasis was significantly lower during exposed periods 
when compared with unexposed periods (sHR: 0.60 [0.38–
0.94], p=0.02), while the risk of incident malignancy did not 
differ between the two periods. The risk of death was also 
lower in those ≤70 years chronically exposed when compared 
with the shortly exposed (adjusted HRs: 0.78 [0.64–0.94] in 
the overall population and 0.73 [0.52–1.01] in those with 
newly developed cancer; Table S3).
Discussion
In this population-based, epidemiological study, there was no 
difference in the risk of incident cancers in people exposed 
for at least 1 year to hydroxychloroquine/chloroquine for 
connective tissue diseases when compared to individuals with 
the same underlying diseases but not exposed to the drugs. On 
the other hand, the risk of metastasis was significantly lower 
during the time of exposure. Also, hydroxychloroquine and 
chloroquine significantly decreased the risk of death, both in 
the overall population and in those diagnosed with incident 
cancer during follow-up.
During the past years, there has been a growing interest in 
the potential antitumor properties of hydroxychloroquine and 
chloroquine through inhibition of autophagy.1–4 Autophagy is 
an intracellular homeostatic pathway by which cells generate 
energy and metabolites by recycling their own nonessential, 
redundant, or damaged organelles and macromolecular com-
ponents.4,22,23 Autophagy can be activated in different cells at 
different stages of tumor growth and have paradoxical roles 
in tumor growth. Before tumorigenesis, autophagy promotes 
survival of normal cells and suppresses tumorigenesis by 
safeguarding against metabolic stress. In contrast, in tumor 
cells that are under metabolic stress as a result of a high 
proliferation rate and exposure to hypoxia from insufficient 
vascularization, autophagy may confer a survival advantage 
and may contribute to tumor growth and spreading.4–6,22,23 
Pharmacologic inhibition of autophagy may be beneficial in 
preventing established tumor growth and spreading. There 
are several ongoing trials that are assessing this effect. On the 
other hand, because autophagy inhibits early tumorigenesis, 
effects of chronic inhibition of autophagy on normal, non-
tumoral cells need to be better understood.
While much is known about the beneficial effects of 
hydroxychloroquine or chloroquine on cancer cell prolif-
eration and risk of metastases both in vitro and in animal 
studies, little is known about its effects on humans. In two 
studies published in 2006 and 2007 by the same team, chlo-
roquine was used as an adjuvant therapeutic agent for the 
treatment of glioblastoma multiforme.7,8 The mean survival 
time of patients receiving chloroquine at 150 mg/day for 
12–18 months was significantly longer than that of patients 





Crude HR p-value Adjusted HR p-value
Death in the overall population, n (%) 636 (7.0) 1,665 (6.9) 0.93 (0.85–1.02) 0.12 0.90 (0.81–1.00) 0.05
 ≤70 years 306 (4.1) 923 (4.5) 0.79 (0.69–0.90) <0.001 0.76 (0.66–0.88) <0.001
 >70 years 330 (22.3) 742 (20.6) 1.06 (0.93–1.21) 0.34 1.09 (0.93–1.26) 0.28
Death in those with newly developed cancer, n (%)a 151 (30.6) 464 (38.0) 0.74 (0.61–0.89) 0.001 0.78 (0.64–0.96) 0.02
 ≤70 years 91 (25.6) 312 (35.3) 0.64 (0.51–0.81) <0.001 0.70 (0.55–0.91) 0.007
 >70 years 60 (43.2) 152 (45.1) 1.00 (0.74–1.34) 0.98 0.98 (0.68–1.42) 0.93
Death in those without newly developed cancer, n (%)a 485 (5.7) 1,201 (5.2) 1.00 (0.90–1.11) 0.99 0.96 (0.86–1.08) 0.53
 ≤70 years 215 (3.0) 611 (3.1) 0.85 (0.72–0.99) 0.04 0.81 (0.68–0.96) 0.02
 >70 years 270 (20.1) 590 (18.0) 1.09 (0.94–1.26) 0.25 1.13 (0.96–1.33) 0.14
Notes: aExcluding basal cell carcinoma. Models adjusted on age, sex, underlying condition, smoking status, past history of cancer, past history of diabetes, past history of 
hypertension, BMI, deprivation index, and number of NSAIDs, metformin, vitamin D, glucocorticoids, methotrexate, and azathioprine prescriptions.
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Antimalarial drugs and cancer
treated with conventional therapy (24 versus 11 months in 
the randomized, placebo-controlled trial8 and 25±3.4 versus 
11.4±1.3 months in the retrospective cohort study).7 In a 
Phase II, double-blind trial, 76 patients with brain metas-
tases were randomized to receive either chloroquine 150 
mg/day for 4 weeks or placebo in association with whole 
brain irradiation.10 The progression-free survival rates of 
brain metastases at 1 year were 83.9% (95% CI: 69.4–98.4) 
for the chloroquine group compared to 55.1% (95% CI: 
33.6–77.6) for the control group, while the overall survival 
rates did not differ between the two groups. There is also a 
prospective, observational study that investigated the effect of 
hydroxychloroquine or chloroquine on the risk of developing 
cancer in 235 patients with systemic lupus erythematosus 
(median time on antimalarial: 53 [6–238] months).9 Among 
patients treated with antimalarials, 2/156 (1.3%) had cancer 
compared with 11/79 (13%) of those not treated (adjusted 
HR: 0.15 [0.02–0.99]).
Our study has several strengths including the use of a large 
population-based sample of individuals of both sexes, across 
all adult age groups, and with many underlying diseases 
and comorbidities. This enabled us to separately compare 
the impact of hydroxychloroquine/chloroquine on the risk 
of non-skin and skin cancers, hematological malignancies, 
metastases, and deaths in an unselected population of indi-
viduals chronically exposed to the drugs in primary care. To 
our knowledge, this is the first study of this kind.
There are, however, some limitations. First, this is an 
observational study rather than a randomized trial, and hence, 
residual confounding cannot be ruled out. For instance, we 
compared individuals chronically exposed to hydroxychloro-
quine/chloroquine to individuals never exposed to the drugs 
during follow-up in order to examine the effects of these 
drugs in well-defined populations and to ease interpretation 
of results. However, it can be argued that this choice may 
have led to a selection bias as unexposed individuals may 
probably be different from the exposed individuals regarding 
general health status or severity of the underlying condition, 
for instance. Nevertheless, many covariates reflecting disease 
severity (such as concomitant prescriptions of glucocorti-
coids or immunosuppressive drugs) or health status (such as 
comorbidities) were accounted for in the analyses. Further, 
results comparing those chronically exposed to those exposed 
for a short period of time (who may be considered as less 
“selected” than the unexposed) showed very similar results. 
Second, we found that the overall incidence rate of metastasis 
was not different between the exposed and unexposed groups 
but was much lower when the individuals were exposed to 
the drugs compared with unexposed periods. This important 
result can be interpreted in two ways. First, hydroxychloro-
quine and chloroquine truly limit the risk of cancer spreading 
during exposure. Second, the drugs were stopped because of 
symptoms due to yet to diagnose metastases (e.g., abdominal 
pain and nausea), and the metastases were diagnosed (and 
recorded) soon after drug withdrawal. This second hypothesis 
could therefore lead to an interpretation bias. Noteworthy, 
most metastases were recorded many months or years after 
drug withdrawal. The third limitation is the low number of 
recorded metastases and hence the wide confidence interval 
of the effect size. This low number of events makes the analy-
sis sensitive to misclassification of the outcome. Moreover, 
on account of these low numbers of events, we were unable 
to assess whether a subtype of primary cancer would ben-
efit more than another to prescribed hydroxychloroquine or 
chloroquine. The fourth limitation is the lack of information 
on the chemotherapies used to treat those diagnosed with 
cancers since these treatments are given at the hospital and 
not routinely recorded in primary care. This is unfortunate 
as most ongoing trials are exploring the potential beneficial 
effects of combining hydroxychloroquine/chloroquine to 
conventional chemotherapies in cancer treatment. Fifth, it 
would have been informative to know if hydroxychloroquine/
chloroquine exposure is associated with less aggressive 
cancers (lower stage or grade, for example), which may in 
turn explain the results found regarding risks of metastasis 
and death. Unfortunately, information regarding the stage or 
grade of cancer is not routinely recorded in THIN. Lastly, it is 
known that non-adherence to hydroxychloroquine in people 
with connective tissue diseases is between 10% and 50%.24 
The results of the present study may therefore be underesti-
mations of the true effects of the drugs.
In conclusion, individuals on long-term exposure to 
hydroxychloroquine or chloroquine for connective tissue 
diseases may be at lower risk of metastatic cancer and death. 
However, these results are limited to observational data, 
and the results of the ongoing randomized controlled trials 
comparing hydroxychloroquine/chloroquine to placebo 
in individuals diagnosed with cancer are eagerly awaited.
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Antimalarial drugs and cancer
Supplementary materials
Table S1 Characteristics of the population shortly exposed for <1 year to hydroxychloroquine
Characteristic Shortly exposed, N=5,265
Age (years) 57 (46–67)
Female, n (%) 4,343 (82.5)
“Start date” Apr 2010 (Jan 2007–Sept 2012)
Duration of follow-up after “start date” (days) 1,476 (818–2,476)
Time between the end of exposure and the end of follow-up (days) 1,369 (697–2,371)
Dosage (mg/day) 399 (267–400)
Duration of exposure (days) 105 (30–210)
Underlying diseases, n (%) 
 Rheumatoid arthritis 3,938 (74.8)
 Systemic lupus erythematosus 774 (14.7)
 Sjogren syndrome 292 (5.5)
 Dermatomyositis/polymyositis 5 (0.1)
 Other connective tissue diseasesa 251 (4.8)
 Light eruption 5 (0.1)
Number of prescriptions ofb
 Methotrexate 0 (0–63)
 Azathioprine 0 (0–1)
 Glucocorticoids 1 (0–56)
 NSAIDs 10 (0–98)
 Metformin 0 (0–6)
 Vitamin D 0 (0–37)
Smoking status, n (%) 
 Nonsmokers 2,551 (48.5)
 Ex-smokers 1,589 (30.2)
 Smokers 1,111 (21.1)
 Missing 14 (0.3)
Townsend deprivation index, n (%)
 0 (less deprived) 172 (3.3)
 1 1,383 (26.3)
 2 1,201 (22.8)
 3 1,111 (21.1)
 4 818 (15.5)
 5 (more deprived) 535 (10.2)
 Missing 45 (0.8)
BMI (kg/m2) 26.5 (23.2–30.9)
Past history of, n (%) 
 Non-skin cancer 236 (4.5)
 Hematological malignancy 34 (0.6)
 Skin cancer 189 (3.6)
 Hypertension 1,330 (25.3)
 Diabetes 427 (8.1)
Incident outcomes after “start date”, n (%) 
 Non-skin cancer
 Breast 66 (1.3)
 Colon 17 (0.3)
 Prostate 9 (0.2)
 Lung 39 (0.7)
 Other or nonspecific codes 79 (1.5)
 Hematological malignancy 42 (0.8)
 Skin cancer 129 (2.5)
 Metastasis 41 (0.8)
 Death 380 (7.2)
Notes: aSystemic sclerosis, antiphospholipid syndrome, mixed and undifferentiated connective tissue diseases. bBefore the date of cancer or a randomly selected date for 
those without cancer. Continuous variables are reported as medians and interquartile range except for the number of medication prescriptions that are reported as medians 
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Table S2 Risk of incident malignancies and metastases – comparison of the hydroxychloroquine/chloroquine exposed and unexposed 
periods
Exposed time




Time at risk (year)
Incidence rate 
(per 100 PY)





















0.56 (0.36–0.86) 0.008 0.60 (0.38–0.94)c 0.02
Notes: *Chronically exposed compared to shortly exposed. aAdjusted on age, sex, underlying condition, smoking status, past history of cancer, deprivation index, and 
number of NSAIDs, metformin, vitamin D, glucocorticoids, methotrexate, and azathioprine prescriptions. bAdjusted on age, sex, underlying condition, smoking status, past 
history of cancer, deprivation index, and number of NSAIDs, vitamin D, glucocorticoids, methotrexate, and azathioprine prescriptions. cAdjusted on age, sex, underlying 
condition, smoking status, past history of cancer, deprivation index, and number of metformin, vitamin D, and glucocorticoids prescriptions.
Abbreviations: NSAIDs, nonsteroidal antiinflammatory drugs; PY, person-years; sHR, sub-distribution hazard ratio.







Crude HR p-value Adjusted HR p-value
Death in the overall population, n (%) 636 (7.0) 380 (7.2) 0.91 (0.80–1.03) 0.15 0.94 (0.82–1.08) 0.37
 ≤70 years 306 (4.1) 197 (4.5) 0.80 (0.67–0.96) 0.01 0.78 (0.64–0.94) 0.01
 >70 years 330 (22.3) 183 (20.0) 1.20 (1.00–1.43) 0.05 1.10 (0.89–1.34) 0.38
Death in those with newly developed cancer, n (%)a 151 (30.6) 107 (38.5) 0.79 (0.61–1.00) 0.05 0.84 (0.65–1.09) 0.20
 ≤70 years 91 (25.6) 62 (32.5) 0.74 (0.54–1.02) 0.07 0.73 (0.52–1.01) 0.06
 >70 years 60 (43.2) 45 (51.7) 0.93 (0.63–1.38) 0.74 0.98 (0.64–1.51) 0.94
Death in those without newly developed cancer, n (%)a 485 (5.7) 273 (5.5) 0.97 (0.84–1.13) 0.72 0.98 (0.84–1.16) 0.85
 ≤70 years 215 (3.0) 135 (3.3) 0.83 (0.67–1.03) 0.09 0.81 (0.64–1.02) 0.08
 >70 years 270 (20.1) 138 (16.7) 1.25 (1.01–1.53) 0.04 1.17 (0.92–1.47) 0.19
Notes: aExcluding basal cell carcinomas. Models adjusted on age, sex, underlying condition, smoking status, past history of cancer, past history of diabetes, past history of 
hypertension, BMI, deprivation index, and number of NSAIDs, metformin, vitamin D, glucocorticoids, methotrexate, and azathioprine prescriptions.
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